Show simple item record

dc.contributor.authorRothwell, Dominic G
dc.contributor.authorAyub, Mahmood
dc.contributor.authorCook, Natalie
dc.contributor.authorThistlethwaite, Fiona C
dc.contributor.authorCarter, Louise
dc.contributor.authorDean, Emma J
dc.contributor.authorSmith, Nigel K
dc.contributor.authorVilla, Shaun
dc.contributor.authorDransfield, Joanne
dc.contributor.authorClipson, Alexandra
dc.contributor.authorWhite, Daniel J
dc.contributor.authorNessa, Kamrun
dc.contributor.authorFerdous, Saba
dc.contributor.authorHowell, Matthew
dc.contributor.authorGupta, Avinash
dc.contributor.authorKilerci, Bedirhan
dc.contributor.authorMohan, Sumitra
dc.contributor.authorFrese, Kristopher K
dc.contributor.authorGulati, Sakshi
dc.contributor.authorMiller, Crispin J
dc.contributor.authorJordan, Allan M
dc.contributor.authorEaton, H
dc.contributor.authorHickson, N
dc.contributor.authorO'Brien, Ciara S
dc.contributor.authorGraham, Donna
dc.contributor.authorKelly, Claire
dc.contributor.authorAruketty, Sreeja
dc.contributor.authorMetcalf, Robert
dc.contributor.authorChiramel, Jaseela
dc.contributor.authorTinsley, Nadina
dc.contributor.authorVickers, Alexander J
dc.contributor.authorKurup, Roopa
dc.contributor.authorFrost, Hannah
dc.contributor.authorStevenson, Julie
dc.contributor.authorSoutham, Siobhan
dc.contributor.authorLanders, Donal
dc.contributor.authorWallace, A
dc.contributor.authorMarais, Richard
dc.contributor.authorHughes, Andrew M
dc.contributor.authorBrady, Ged
dc.contributor.authorDive, Caroline
dc.contributor.authorKrebs, Matthew G
dc.date.accessioned2019-06-04T09:44:27Z
dc.date.available2019-06-04T09:44:27Z
dc.date.issued2019en
dc.identifier.citationRothwell DG, Ayub M, Cook N, Thistlethwaite F, Carter L, Dean E, et al. Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. Nat Med. 2019; 25(5):738-43.en
dc.identifier.pmid31011204en
dc.identifier.doi10.1038/s41591-019-0380-zen
dc.identifier.urihttp://hdl.handle.net/10541/621823
dc.description.abstractNext-generation sequencing (NGS) of circulating tumor DNA (ctDNA) supports blood-based genomic profiling but is not yet routinely implemented in the setting of a phase I trials clinic. TARGET is a molecular profiling program with the primary aim to match patients with a broad range of advanced cancers to early phase clinical trials on the basis of analysis of both somatic mutations and copy number alterations (CNA) across a 641 cancer-associated-gene panel in a single ctDNA assay. For the first 100 TARGET patients, ctDNA data showed good concordance with matched tumor and results were turned round within a clinically acceptable timeframe for Molecular Tumor Board (MTB) review. When a 2.5% variant allele frequency (VAF) threshold was applied, actionable mutations were identified in 41 of 100 patients, and 11 of these patients received a matched therapy. These data support the application of ctDNA in this early phase trial setting where broad genomic profiling of contemporaneous tumor material enhances patient stratification to novel therapies and provides a practical template for bringing routinely applied blood-based analyses to the clinic.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1038/s41591-019-0380-zen
dc.titleUtility of ctDNA to support patient selection for early phase clinical trials: the TARGET studyen
dc.typeArticleen
dc.contributor.departmentClinical Experimental Pharmacology Group, CRUK Manchester Institute, Manchester, UKClinical Experimental Pharmacology Group, CRUK Manchester Institute, Manchester, UKen
dc.identifier.journalNature Medicineen


This item appears in the following Collection(s)

Show simple item record